Phase II Study of Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Progression-free survival (PFS)
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-tumor and anti-virus protein for injection in treating patients with advanced neuroendocrine tumors who have failed standard treatment or are unable to receive standard treatment.
详细描述
This is a Phase Ⅱ exploratory clinical study. The purpose of this study is to evaluate the efficacy and safety of recombinant anti-tumor and anti-virus protein for injection in treating patients with advanced neuroendocrine tumors who have failed standard treatment or are unable to receive standard treatment.
Recombinant anti-tumor and anti-virus protein for injection, 10μg,im,3 times for the first week, followed by 20μg for two weeks, and followed a maintenance dose of 30μg, the frequency of administration is three times per week. Treatment continued until the patient died or had unacceptable toxicity or had disease progression or required to discontinue the treatment. At the time of disease progression, if investigators believe patients can continue to benefit from the investigational product, patients may be provided with recombinant anti-tumor and anti-virus protein for injection,but only survival follow-up datas will be recorded.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have been fully aware of the study and voluntarily signed the informed consent.
- •At least 18 years old.
- •Have a confirmed histological or cytological diagnosis of low- or intermediate-grade advanced NETs (unresectable or metastatic), the pathology must meet one of the following criteria: (a) primary site of lung or thymus (carcinoid) with mitotic count of ≤ 10/10 High Power Field [HPF]) (b) other primary site (including primary unknown) with mitotic count of ≤ 20/10 High Power Field [HPF] and Ki67 index of ≤ 20%，or with Ki67 index of > 20% and well-differentiated.
- •Patients who have failed standard treatment or are unable to receive standard treatment, and have disease progression within the past 12 months;
- •At least one measurable lesion according to the RECIST 1.1 criteria that has not been previously locally treated.
- •ECOG performance status 0, 1 or
- •Minimum of 4 weeks since any local radiotherapy or surgery for the control of symptoms or severe complications(local radiotherapy for the control of bone metastases is not the limit)，and adequately recovered from toxicities of any prior therapy).
- •Life expectancy of at least 3 months.
排除标准
- •Prior treatment with Recombinant Anti-tumor and Anti-virus Protein for Injection.
- •Prior treatment with Interferon.
- •Pregnancy or breast-feeding women or women who may be pregnant were positive drug test before administration.
- •Patient of child-bearing potential(male or less than 1 year postmenopausal women) were reluctant to take contraceptive measures.
- •Patient who were allergic to Interferon-α or who had interferon-α antibody.
- •Have brain metastases or previous history of brain metastases or history of seizures.
研究组 & 干预措施
Experimental
Recombinant anti-tumor and anti-virus protein for injection(Novaferon), three times per week.
干预措施: Recombinant anti-tumor and anti-virus protein for injection (Novaferon) (Drug)
结局指标
主要结局
Progression-free survival (PFS)
时间窗: 1 year
PFS is defined as the length of time from random assignment to disease progression or to death resulting from any cause other than the progress.
Disease control rate(DCR)
时间窗: 1 year
DCR is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments.
次要结局
- Overall response rate(ORR)(1 year)
- Adverse Events(AEs)(1 year)
- Overall survival (OS)(3 years)